GGrantIndex
← Search

OHSU Knight Federated Learning Network Prototype to Support Multimodal Cancer Models

$299,750P30FY2023CANIH

Oregon Health & Science University, Portland OR

Investigators

Linked publications, trials & patents

Paper 39764100Paper 39763867Paper 39605535Paper 39435649Paper 39386578Paper 39375962Trial NCT07434128Trial NCT07278440Trial NCT07089940Trial NCT05705492Trial NCT04247425Trial NCT04172493Trial NCT04104139Trial NCT04061980Trial NCT04005690Trial NCT03961672Trial NCT03960177Trial NCT03699995Trial NCT03677531Trial NCT03649880Trial NCT03626285Trial NCT03613259Trial NCT03544125Trial NCT03479268Trial NCT03418025Trial NCT03406013Trial NCT03361436Trial NCT03347617Trial NCT03325166Trial NCT03280277Trial NCT03270059Trial NCT03261180Trial NCT03234309Trial NCT03135782Trial NCT03097588Trial NCT03028935Trial NCT03010358Trial NCT03009201Trial NCT02890979Trial NCT02869412Trial NCT02857218Trial NCT02779283Trial NCT02736617Trial NCT02522715Trial NCT02504359Trial NCT02503358Trial NCT02501759Trial NCT02498951Trial NCT02427841Trial NCT02359097Trial NCT02355262Trial NCT02312557Trial NCT02228265Trial NCT02100189Trial NCT02099864Trial NCT02092324Trial NCT02070705Trial NCT02050919Trial NCT01913015Trial NCT01748942Trial NCT01689987Trial NCT01649505Trial NCT01635413Trial NCT01620216Trial NCT01532687Trial NCT01498978Trial NCT01441882Trial NCT01422408Trial NCT01253642Trial NCT01031953Trial NCT01005914Trial NCT00983398Trial NCT00978562Trial NCT00900302Trial NCT00900068Trial NCT00900055Trial NCT00899795Trial NCT00899522Trial NCT00843167Trial NCT00822848Trial NCT00764517Trial NCT00722072Trial NCT00691652Trial NCT00662103Trial NCT00660543Trial NCT00659126Trial NCT00627276Trial NCT00516542Trial NCT00482274Trial NCT00425386Trial NCT00324324Trial NCT00303849Trial NCT00293475Trial NCT00253721Trial NCT00253643Trial NCT00238433Trial NCT00227682Trial NCT00103038Trial NCT00075387Patent 9279811

Abstract

PROJECT SUMMARY/ABSTRACT Traditional data-sharing models typically centralize de-identified data for analysis. Patient records have become more multifaceted and high-dimensional such that de-identification alone is inadequate to safeguard privacy. Privacy violations can result in harms to patients that can be both deontological (ethically problematic) or consequentialist (harm such as discrimination, financial consequences, and stigma). Current regulatory guidelines are not designed for the complexity of AI/ML. Moreover, each academic medical center will have their own ethics boards, governance models, privacy standards and security requirements. Risk of a privacy breach limits access and sharing of patient data — a barrier to research across cancer centers and academic medical centers. Given its outstanding strengths in precision oncology, computational biology, machine learning, clinical curation, data governance and data quality and regional data sharing, OHSU Knight Cancer Institute is uniquely situated to assist NCI in the development of a federated learning network. The long-term objective is to develop the best practices and guidance to support large-scale federated learning across cancer centers to achieve optimal benefit through broad data sharing. In the near term, the focus of this project is to support the development and testing of a federated learning network prototype. To do this, the OHSU Knight Cancer Institute proposes the following aims. Aim 1 is to develop a multi-modal deep learning model to predict tumor mutational burden in prostate cancer. Aim 2 is to implement and evaluate our federated learning prototype focusing on privacy, compliance and bias reduction. This will also include assessment of the impact of adversarial attacks and how well different defense strategies mitigate this. Finally, Aim 3 is the evaluation of the federated model on the federated learning network in collaboration with partner sites (other cancer centers, NCI).

View original record on NIH RePORTER →